Agentic AI for Large Pharma
Scale Global Clinical Execution with Agentic AI for Large Pharma
Large pharma organizations managing 100–300+ concurrent clinical trials need execution capacity that can keep pace with portfolio complexity. Biometrics and data-management workflows increase costs, while 6–8-month database-lock delays can defer $3-5 million per study.
Maxis AI delivers an AI Workforce for Clinical Trials, adding a supervised execution layer across Biometrics, data management, Governance, and portfolio oversight-helping global teams scale execution without proportionally increasing headcount.
Human-in-the-loop validation · Audit traceability
Each offering maps directly to an execution constraint limiting portfolio throughput for pharma R&D leaders.
Portfolio Data Quality and RBQM Oversight
- Unified visibility across trials and CRO partners
- Continuous detection of data quality risks
AI-Driven Clinical Data Management
- Automated data cleaning and validation
- Faster database readiness and submission timelines
AI-Supported Statistical Programming
- Automated dataset preparation and validation
- Improved biometrics efficiency and scalability
Operational Oversight and Governance
- Continuous monitoring across clinical workflows
- Stronger governance visibility across global programs
Common Clinical Execution Challenges for Large Pharma
Execution scalability typically constrains biometrics and readiness layers.
Portfolio data quality remains fragmented
Manual review slows database readiness
CRO execution varies across programs
Biometrics throughput becomes a bottleneck
Protocol and SAP changes delay submissions
AI governance slows enterprise adoption
Business Outcomes of Agentic AI for Large Pharma
With Agentic AI for large pharma, governed execution becomes structured and globally coordinated across clinical development programs.
Unified data quality execution across studies
Faster database readiness with supervised resolution
More consistent CRO and vendor oversight
Improved biometrics throughput and readiness
Better control over protocol and SAP changes
Pilot-safe AI adoption with governance built in
Recommended Approach
Deploy supervised AI execution across biometrics and data management workflows first — the highest-leverage layers for large pharma, supported by our AI deployment and governance services. Sponsors that do this accelerate database lock by 40–50%, recover $3–5M per trial, and establish unified portfolio-level oversight across CRO partners.
5–300+ Trial Oversight, 8–12 Week Risk Forecasting
How Maxis AI supported a Large Pharma company achieve RBQM oversight for 5–300+ trials, forecasting risks 8–12 weeks early, reducing queries 60–75%, and speeding DB lock by 30%.
5–300+
Scalable Portfolio Oversight
30%
Faster DB lock
8–12 Wks
Predictive risk forecasting
60–75%
Query Reduction
All You Need to Know
Agentic AI for Large Pharma enables pharmaceutical organizations to scale clinical execution across global portfolios through supervised AI agents operating within governed workflows. Rather than only generating recommendations, the AI Workforce executes structured work across study startup, clinical data management, biometrics, medical writing, and oversight while maintaining human validation. This approach improves execution consistency, increases operational capacity, and strengthens AI-enabled trial governance without disrupting existing quality systems or regulatory controls.
Maxis AI supports AI-driven clinical operations for pharma by introducing a supervised execution layer across regulated clinical workflows. AI agents execute approved operational tasks while human experts validate outputs at defined checkpoints. The AI Workforce supports study startup, enrollment, clinical data management, statistical programming, medical writing, and portfolio oversight. This enables large pharmaceutical organizations to improve execution speed, operational consistency, and portfolio throughput while maintaining governance, traceability, and regulatory readiness.
The AI Workforce executes structured operational work across study startup, enrollment coordination, clinical data management, query resolution, statistical programming, medical writing, and operational oversight. Every workflow operates within defined execution boundaries, human validation checkpoints, and governance controls. Rather than replacing clinical teams, the AI Workforce expands execution capacity, helping large pharmaceutical organizations improve consistency, reduce operational bottlenecks, and scale global clinical execution with confidence.
Maxis AI strengthens AI-enabled trial governance by ensuring every AI-executed workflow follows predefined operational boundaries, approval rules, and validation standards. Organizations define supervision thresholds, workflow permissions, and output requirements before execution begins. Every action is recorded with complete audit traceability to support quality management and regulatory inspections. This governance-first approach enables organizations to scale AI adoption responsibly while maintaining compliance with internal quality frameworks.
Yes. Large pharmaceutical organizations typically begin with a single, well-defined workflow to establish governance, validation criteria, and measurable outcomes. Once execution consistency is demonstrated, additional workflows can be introduced using the same operational controls and supervision model. This phased approach reduces implementation risk while allowing Agentic AI for Large Pharma to scale across clinical operations in a structured, evidence-based manner.
Explore the Agentic AI Platform.
See how AI agents are transforming study startup, data management, oversight, and regulatory submissions.